Resolve the exposure structure
Keep the parties, agreements, policies, invoices, and projects connected but distinct.
Bring connected financial evidence to trade credit, surety, and premium-finance reviews. Understand the counterparty, contractual obligations, and changing conditions without losing the structure of the underlying exposure.
Explore your segment
Choose a segment to explore the evidence, financial relationships, and changes that matter to the review. The analytical scope follows the product and the information your institution is permitted to use.
Connect seller, buyer, invoice, and supplied policy evidence as distinct objects. Review supported aging, buyer concentration, and documented limits without assuming that every invoice is covered.
Collection deterioration and changes in buyer concentration or eligible exposure.

Keep the parties, agreements, policies, invoices, and projects connected but distinct.
Review supported capacity, concentration, obligations, and changes using the relevant contract definitions.
Carry findings and unresolved questions into underwriting or monitoring. Coverage, pricing, claims, and intervention remain with the institution.
Bring the agreed evidence snapshot, supported calculations, and findings into a reviewable underwriting context.
Explore underwritingMonitor existing relationships and reassess permitted new evidence against the baseline, with source limitations visible.
Explore monitoringExplore the detailed guides for Canada and the United States, including dated market context, assessment methods, implementation considerations, and source references.
Where is receivable exposure concentrated, and what do the terms support?
Read guideINDUSTRY GUIDEHow does supported operating capacity compare with the commitments?
Read guideINDUSTRY GUIDEWhich amounts are owed, potentially recoverable, and actually received?
Read guideAgree the evidence sources, jurisdiction, product definitions, and decision responsibilities before implementation. Test missing information and exceptions as carefully as completed assessments.
These workflows support financial-risk assessment and monitoring. Policy administration, coverage decisions, pricing, claims, and customer intervention remain with the institution.
No. Market aggregates provide context, not a counterparty-level conclusion. Use authorized evidence and the specific terms of the exposure under review.
Public market observations provide context, not an Amlok performance claim or a universal approval threshold. Preserve geography, reporting period, product population, and denominator when comparing results. Page illustrations are fictional.
A point-in-time decision does not need to become a blind spot for the life of the deal.
